Midriodavi (Cyclopentolate Hydrochloride)

Cyclopentolate Hydrochloride, the active ingredient in Midriodavi, is an anticholinergic (muscarinic antagonist) presented as an ophthalmic solution for ocular use. It is employed to dilate the pupil and induce cycloplegia for diagnostic and therapeutic eye procedures. Midriodavi is marketed in the European Union and complies with relevant regulatory standards.

GNH USA supplies Midriodavi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Midriodavi acts on muscarinic receptors in the eye to produce mydriasis and cycloplegia, facilitating several ophthalmic indications. - Diagnostic eye examinations: provides pupil dilation for thorough retinal and optic nerve assessment. - Anterior uveitis: induces cycloplegia to relieve pain, prevent adhesions, and aid inflammation control. - Intraocular surgery: maintains a dilated pupil to improve surgical access and safety.

Cyclopentolate may cause ocular and systemic reactions, most of which are mild and transient.

Common Side Effects: - Stinging or burning sensation upon instillation. - Transient blurred vision. - Photophobia due to prolonged pupil dilation. - Increased intra‑ocular pressure in susceptible individuals. - Allergic conjunctivitis (redness, itching). - Mild headache.

Serious or Rare Side Effects: - Acute angle‑closure glaucoma. - Severe allergic reaction or anaphylaxis. - Systemic anticholinergic toxicity (dry mouth, tachycardia, confusion). - Persistent mydriasis lasting >24 hours. - Corneal edema or epithelial defects. - Vision loss if complications are untreated.

Before prescribing Midriodavi, clinicians should consider patient‑specific factors and proper handling. - Assess intra‑ocular pressure: avoid in patients with narrow‑angle glaucoma. - Verify hypersensitivity: do not use in individuals allergic to cyclopentolate or other anticholinergics. - Use caution in pediatric patients: systemic absorption may be higher. - Avoid concurrent use with other mydriatics unless directed by a specialist. - Pregnancy and lactation: prescribe only if the potential benefit justifies the potential risk. - Store at room temperature: keep in the original container, protect from light and moisture.

Cyclopentolate can interact with other medications affecting ocular tone or systemic anticholinergic load.

Major Interactions (Avoid): - Systemic anticholinergics (e.g., atropine): additive anticholinergic effects may increase systemic toxicity. - Adrenergic agents (e.g., phenylephrine): may cause excessive pupil dilation and raise intra‑ocular pressure. - Monoamine oxidase inhibitors: risk of severe hypertension when combined with sympathomimetic eye drops.

Moderate Interactions (Monitor Closely): - Topical non‑steroidal anti‑inflammatory drugs: may increase ocular irritation. - Beta‑blocker eye drops: monitor intra‑ocular pressure for additive effects. - Other cycloplegics (e.g., tropicamide): risk of over‑cycloplegia; adjust dosing as needed.